First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study
Journal of Thoracic Oncology · 2025
DOI: 10.1016/j.jtho.2025.02.021 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2025. Verfasst von Yi-Long Wu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Sciences, Guangzhou…. Hauptthemen laut MEDLINE: Crizotinib, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
INTRODUCTION: Lorlatinib, a third-generation anaplastic lymphoma kinase inhibitor, reported significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patients with previously untreated advanced anaplastic lymphoma kinase-positive NSCLC. Efficacy was similar in the Asian subgroup. We present an updated subgroup analysis in Asian patients after five years of follow-up. METHODS: Patients were randomly (1:1) assigned to receive lorlatinib 100 mg once daily (n = 59) or crizotinib 250 mg twice daily (n = 61). This post hoc analysis presents updated investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS: After a median follow-up of 62.4 months for lorlatinib and 55.1 months for crizotinib, median PFS was not reached (NR, 95% confidence interval [CI]: 64.3‒NR) and 9.2 months (95% CI: 7.2‒12.7), respectively (hazard ratio [HR] = 0.22, 95% CI: 0.13‒0.37); the five-year PFS was 63% (95% CI: 49-74) and 7% (95% CI: 2-17). The objective response rate was 81% (95% CI: 69-90) with lorlatinib and 59% (95% CI: 46‒71) with crizotinib. In patients with baseline brain metastases, the intracranial objective response rate was 69% (95% CI: 39‒91) with lorlatinib and 6% (95% CI:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Sciences, Guangzhou, People's Republic of China. Electronic address: yylwu@live.cn.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singapore.
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Sciences, Guangzhou, People's Republic of China.
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
- School of Medicine and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; I…
Förderung
- Pfizer
Zitieren
APA
Wu, Y. L., Kim, H. R., Soo, R. A., Zhou, Q., Akamatsu, H., Chang, G. C., Chiu, C. H., Hayashi, H., Kim, S. W., Goto, Y., Kato, T., Zhou, J., Lee, V. H., Nishio, M., Han, B., Kim, D. W., Lu, S., Polli, A., Martini, J. F., …, & Mok, T. (2025). First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2025.02.021
Vancouver
Wu YL, Kim HR, Soo RA, Zhou Q, Akamatsu H, Chang GC, et al. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. Journal of Thoracic Oncology. 2025. doi:10.1016/j.jtho.2025.02.021
BibTeX
@article{Wu2025,
author = {Wu, Yi-Long and Kim, Hye Ryun and Soo, Ross A and Zhou, Qing and Akamatsu, Hiroaki and Chang, Gee-Chen and Chiu, Chao-Hua and Hayashi, Hidetoshi and Kim, Sang-We and Goto, Yasushi and Kato, Terufumi and Zhou, Jianying and Lee, Victor Ho-Fun and Nishio, Makoto and Han, Baohui and Kim, Dong-Wan and Lu, Shun and Polli, Anna and Martini, Jean-François and Toffalorio, Francesca and Wong, Chew Hooi and Mok, Tony},
title = {First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study},
journal = {Journal of Thoracic Oncology},
year = {2025},
doi = {10.1016/j.jtho.2025.02.021}
}
EUVIMED